Zynerba Pharmaceuticals CEO Armando Anido joins Natalie Stoberman from the Proactive studios to share results of its phase 2 trial of Zygel.
Anido says data from the Phase 2 INSPIRE trial with Zygel in children and adolescents with with 22q11.2 deletion syndrome has continued to show improvement in anxiety-related and behavioural symptoms.